News
Public · Published
Truist Securities upgrades Edwards Lifesciences to Buy from Hold, raises price target to $113 from $95
Truist Securities upgraded Edwards Lifesciences from Hold to Buy and raised its price target from $95 to $113. The new target is 18.9% higher than the previous target and implies 18.7% upside from the November 3 closing price of $95.19.
Published:
Updated:
What happened
Truist Securities upgraded Edwards Lifesciences from Hold to Buy and raised its price target from $95 to $113. The new target is 18.9% higher than the previous target and implies 18.7% upside from the November 3 closing price of $95.19.
Confirmed
Global impact / market context
The higher target and Buy rating signal greater optimism from Truist about Edwards Lifesciences’ prospects, but they do not guarantee the share price will rise. If investors act on the assessment, buying could support the shares; the article gives no reasons behind the change.
Analyst inference
This is an analyst rating change, not a company announcement or reported change in operations. The stated upside compares Truist’s target with the November 3 close; it does not establish future performance, and the article provides no broader industry or market context.
Confirmed
What to watch
- Look for any further analyst changes or explanations for Truist’s upgrade; the article does not say what prompted the more positive rating or higher target. Analyst inference
- Compare later reported company results with the expectations reflected in the $113 target, while remembering that a price target is an analyst estimate, not a promised outcome. Analyst inference
- Track whether Edwards Lifesciences issues any company updates that could clarify its prospects; none are included in the supplied article. Analyst inference
Evidence
- Original source link unavailable